identification ampk substrate smpd3 provide first link nicotineactivated ampk ceramide metabolism pathway may also explain promotion ceramide level cigarette smoke serum tissue lung liver abdominal aorta31,32 addition highfat diet highcholesterol diet show nicotine intake another important inducer intestinederived ceramide production basis find study indicate intervention either microbial nicotine degrader target base intestinal ampkαsmpd3ceramide axis show translational potential treatment nicotineassociated nash three cohort include study cohort 1 approve ethical committee first affiliate hospital zhejiang university school medicine 2021875. participant provide write inform consent cohort 2 cohort 3 approve ethical committee first affiliate hospital wenzhou medical university 2016246 inform write consent obtain participant cohort 1 terminal ileum mucosa biopsy serum stool sample collect 30 nonsmoker 30 smoker characteristic participant list supplementary table 1 2. participant diagnose colon polyp polypectomy colonoscopy obtain trace amount terminal ileal mucosa tissue obvious abnormality cohort 2 serum stool sample collect 41 smoker diagnose biopsyconfirmed nafld histological sample score accord nashclinical research network crn score system brief na calculate sum three histological component include steatosis grade 03 balloon grade 02 lobular inflammation grade 03. patient na ≥5 correlate definite nash patient na 3 4 correlate borderline nash biopsy score le 3 diagnose nafl characteristic participant list supplementary table 3 4. cohort 3 serum stool sample 42 nonsmoker diagnose biopsyconfirmed nafld diagnosis score nafld describe characteristic participant list supplementary table 5 6. exclusion criterion cohort 13 diabetic ketoacidosis hyperglycaemic hyperosmolar state patient decompensated cirrhosis stage 35 chronic kidney disease inflammatory bowel disease cancer pulmonary tuberculosis aid alcoholism disease judge clinician unsuitable biopsy take antibiotic include rifaximin probiotic prebiotics protonpump inhibitor laxative last 3 month clinical information collect accord standard procedure collect metadata cover participant anthropometric feature information relate health status age sex dietary habit peripheral blood sample centrifuge 1,000g 4 °c 5 min obtain serum level blood biochemical indicator triglyceride tc ast alt measure use autoanalyzer biotek instrument 800ts framingham risk score 10yearqrisk3 score calculate accord previously report faeces collect collection cup immediately freeze 80 °c analysis mucosa biopsy sample collect colonoscopy terminal ileum sample obvious abnormality spf mouse c57bl6j strain randomly divide different group house 35 per cage maintain standard laboratory condition free access rodent fee water department experimental animal science peking university health science center national cancer institute national institute health nih specifically light 08:00 20:00 temperature keep 2124 °c humidity 4070. gf c57bl6j gempharmatech breed within sterile vinyl isolators maintain gnotobiotic mouse facility department experimental animal science peking university health science center animal experiment comply protocol animal use treatment euthanasia approve peking university permit la2020480 national cancer institute animal care use committee nih animal protocol lm016 lm096 prkaa1 mouse purchase jackson laboratory 014141. achieve intestinalepitheliumspecific ampkα1 disruption prkaa1 mouse cross villincre mouse gift d. l. gumucio obtain prkaa1 mouse villincre mouse express cre recombinase villus crypt epithelial cell small large intestine successful knockout prkaa1 assess extend data fig 4f prkaa2 mouse purchase gempharmatech t013159 cross villincre mouse obtain prkaa2 mouse successful knockout prkaa2 assess extend data fig 4f male mouse age 8 week feed hfhcd research diet d09100310 assay drink mouse model spf mouse gf mouse treat nicotine 10 μg ml sigmaaldrich 54115 sweet water contain 23.1 g l dfructose sigmaaldrich f0127 18.6 g l dglucose sigmaaldrich g8270 assay mouse smoke exposure model mouse expose 60 mg cigarette smoke total suspend particulate matter 2 week 2 h per day mouse subcutaneous injection model mouse administer nicotine 0.5 mg kg saline daily 2 week gw4869 selleck chemical s7609 treatment spf mouse treat control 10 mg kg gw4869 daily gavage ceramide d18:116:0 avanti polar lipid 860692 supplementation littermate prkaa1 prkaa1 mouse give vehicle 10 mg kg ceramide d18:116:0 daily i.p injection bacterial colonization spf mouse treat 2 × 10 cfu b. xylanisolvens nicxknockout b. xylanisolvens 200 μl sterile anaerobic pb gavage every 3 day wt nicxknockout b. xylanisolvens grow anaerobically bhi medium culture wash concentrate anaerobic pb final concentration 1 × 10 cfu per ml strict anaerobic condition determination cfu per ml perform dilutionplate method use bhi medium contain 1 agarose anaerobic condition analysis mouse bodymass composition body fat content fat ratio measure calculate use mri bodyfat measurement instrument echomri700 echomri 1 week euthanasia biochemical analysis hepatic serum triglyceride cholesterol nonesterified fatty acid level determine use assay kit wako diagnostics wako chemical accord manufacturer 's instruction alt ast level assess use commercial alt ast assay kit catachem concentration nicotine hpb measure liquid chromatography couple tandem mass spectrometry lcmsms tissue analysis tissue sample approximately 0.1 g homogenize addition 10 methanol aqueous solution subsequently 20 μl naoh 1 1 ml ethyl acetate 10 μl internal standard 500 ng ml nicotined4 nicotine hpb add 100 μl homogenate mixture rapidly mix centrifuge 13,000 rpm 10 min subsequently 900 μl supernatant volatilize nitrogen gas sediment dissolve 100 μl 70 aqueous acetonitrile vv serum culture medium bacteria 100 μl sample prepare describe 5 μl supernatant analyse use qtrap 5500 system ab sciex water xbridge amide column 100 × 4.6 mm inner diameter 3.5 μm mobile phase mixture acetonitrile b water contain 0.1 formic acid 2 mm ammonium formate constant flow rate 0.5 ml min proportion mobile phase b maintain 25 isocratic elution analytes mh measure mz 163.1130.1 nicotine mz 166.1106.0 hpb mz 167.1134.1 nicotined4 lower relative s.d value le 10 detect within day recovery analytes higher 97. metagenomic sequence perform previously describe dna 700 ng per sample use sample preparation sequence library generate use ultra dna library prep kit illumina manufacturer 's recommendation index code use annotate sequence sample fragment dna end repair polya tail ligate sequence adaptor illumina sequence pcr amplification dna purification perform use ampure xp system dna concentration measure use qubit dna assay kit qubit 2.0 fluorometer dilute 2 ng 08l library insert size assess use agilent bioanalyzer 2100 system cluster indexcoded sample perform cbot cluster generation system use hiseq 250 pe cluster kit accord manufacturer 's instruction cluster generation library sequence illumina hiseq 250 platform 150 bp pairedend read generate sequence data convert fastq file use bcl2fastq read qualitycontroltrimmed use trimmomatic follow parameter pe thread 10 phred33 validatepairs illuminaclip truseq3pe.fa:2:30:10 leading:3 trailing:3 minlen:50. use metaphlan2 ref taxonomic analysis follow parameter ignoreviruses ignorearchaea ignoreeukaryotes followup analysis perform use microbiomeanalyst αdiversity estimate basis gene profile sample accord ace chao1 shannon index lefse analysis perform use galaxy b. xylanisolvens strain j1101 isolate human faeces previously describe strain identify compare 16 rrna gene sequence ncbi reference database